 Jessica Cardenas
Concepts (222)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Venous Thromboembolism | 11 | 2024 | 337 | 4.780 |
Why?
| | Wounds and Injuries | 25 | 2026 | 930 | 3.490 |
Why?
| | Blood Coagulation Disorders | 10 | 2023 | 190 | 2.870 |
Why?
| | Shock, Hemorrhagic | 8 | 2026 | 198 | 2.810 |
Why?
| | Thrombosis | 10 | 2026 | 399 | 2.660 |
Why?
| | Hemostasis | 12 | 2022 | 100 | 2.630 |
Why?
| | Endothelial Cells | 8 | 2026 | 832 | 2.160 |
Why?
| | Thrombin | 14 | 2026 | 167 | 1.990 |
Why?
| | Thrombophilia | 4 | 2022 | 90 | 1.530 |
Why?
| | Enoxaparin | 3 | 2022 | 68 | 1.470 |
Why?
| | Endothelium, Vascular | 7 | 2026 | 951 | 1.320 |
Why?
| | Syndecan-1 | 6 | 2023 | 41 | 1.270 |
Why?
| | Fibrinolysis | 6 | 2019 | 162 | 1.260 |
Why?
| | Blood Transfusion | 8 | 2025 | 397 | 1.200 |
Why?
| | Thrombelastography | 14 | 2023 | 175 | 1.090 |
Why?
| | Antithrombin III | 3 | 2022 | 17 | 1.000 |
Why?
| | Hemorrhage | 7 | 2023 | 798 | 0.910 |
Why?
| | Blood Component Transfusion | 6 | 2021 | 100 | 0.860 |
Why?
| | von Willebrand Factor | 2 | 2025 | 84 | 0.830 |
Why?
| | Fibrinogen | 5 | 2023 | 179 | 0.790 |
Why?
| | Blood Coagulation | 10 | 2025 | 269 | 0.760 |
Why?
| | Cadherins | 2 | 2023 | 201 | 0.750 |
Why?
| | Platelet Transfusion | 2 | 2019 | 78 | 0.680 |
Why?
| | Shock | 2 | 2021 | 105 | 0.670 |
Why?
| | Blood Platelets | 7 | 2022 | 389 | 0.640 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2024 | 449 | 0.620 |
Why?
| | Plasminogen Activator Inhibitor 1 | 3 | 2019 | 89 | 0.590 |
Why?
| | alpha-2-Antiplasmin | 2 | 2019 | 3 | 0.590 |
Why?
| | Periodicals as Topic | 1 | 2021 | 200 | 0.580 |
Why?
| | Plasma | 1 | 2020 | 222 | 0.560 |
Why?
| | Anticoagulants | 5 | 2023 | 725 | 0.540 |
Why?
| | Antithrombins | 3 | 2022 | 69 | 0.530 |
Why?
| | Humans | 62 | 2026 | 142526 | 0.520 |
Why?
| | Cell-Derived Microparticles | 2 | 2015 | 73 | 0.510 |
Why?
| | Prospective Studies | 17 | 2025 | 7862 | 0.500 |
Why?
| | Injury Severity Score | 10 | 2025 | 573 | 0.490 |
Why?
| | Brain Injuries, Traumatic | 5 | 2025 | 417 | 0.460 |
Why?
| | Capillary Permeability | 3 | 2023 | 133 | 0.460 |
Why?
| | Endothelial Progenitor Cells | 1 | 2015 | 20 | 0.450 |
Why?
| | Inflammation | 5 | 2026 | 2867 | 0.450 |
Why?
| | Fibrinolysin | 1 | 2014 | 21 | 0.420 |
Why?
| | Tissue Plasminogen Activator | 2 | 2017 | 239 | 0.400 |
Why?
| | Adult | 30 | 2026 | 39715 | 0.390 |
Why?
| | Middle Aged | 28 | 2026 | 35049 | 0.380 |
Why?
| | Hemostatics | 2 | 2023 | 60 | 0.370 |
Why?
| | Male | 35 | 2026 | 70910 | 0.370 |
Why?
| | Obesity, Morbid | 1 | 2015 | 277 | 0.340 |
Why?
| | Arthroplasty, Replacement, Knee | 1 | 2015 | 372 | 0.310 |
Why?
| | Glycocalyx | 3 | 2019 | 29 | 0.290 |
Why?
| | Thrombomodulin | 3 | 2023 | 13 | 0.270 |
Why?
| | Postoperative Complications | 2 | 2023 | 2862 | 0.270 |
Why?
| | Blood Coagulation Tests | 5 | 2025 | 72 | 0.260 |
Why?
| | Risk Factors | 8 | 2025 | 10593 | 0.260 |
Why?
| | Fibrin | 3 | 2023 | 90 | 0.260 |
Why?
| | Rats, Sprague-Dawley | 4 | 2023 | 2523 | 0.260 |
Why?
| | Resuscitation | 4 | 2023 | 298 | 0.250 |
Why?
| | Female | 30 | 2026 | 76624 | 0.250 |
Why?
| | Blood Preservation | 2 | 2021 | 307 | 0.250 |
Why?
| | Cohort Studies | 5 | 2022 | 5858 | 0.250 |
Why?
| | Endothelium | 2 | 2023 | 119 | 0.230 |
Why?
| | Fibrin Fibrinogen Degradation Products | 2 | 2023 | 92 | 0.230 |
Why?
| | Retrospective Studies | 7 | 2024 | 16626 | 0.230 |
Why?
| | Interleukin-8 | 2 | 2023 | 269 | 0.220 |
Why?
| | ABO Blood-Group System | 1 | 2025 | 53 | 0.220 |
Why?
| | Oxidative Stress | 2 | 2025 | 1351 | 0.220 |
Why?
| | Platelet Function Tests | 6 | 2022 | 34 | 0.210 |
Why?
| | Animals | 10 | 2026 | 37697 | 0.210 |
Why?
| | Coagulants | 1 | 2023 | 21 | 0.210 |
Why?
| | Endothelial Protein C Receptor | 1 | 2023 | 6 | 0.200 |
Why?
| | Sulfates | 1 | 2023 | 50 | 0.190 |
Why?
| | Rats | 3 | 2023 | 5585 | 0.190 |
Why?
| | Platelet Aggregation | 5 | 2022 | 102 | 0.190 |
Why?
| | Chemoprevention | 1 | 2023 | 95 | 0.190 |
Why?
| | Chemokines | 1 | 2023 | 223 | 0.190 |
Why?
| | Mice, Inbred C57BL | 2 | 2026 | 5967 | 0.180 |
Why?
| | Sarcoidosis, Pulmonary | 1 | 2023 | 86 | 0.180 |
Why?
| | Interleukin-6 | 2 | 2023 | 780 | 0.180 |
Why?
| | Venous Thrombosis | 1 | 2023 | 194 | 0.170 |
Why?
| | Pulmonary Embolism | 1 | 2023 | 239 | 0.170 |
Why?
| | Infusion Pumps | 1 | 2020 | 34 | 0.170 |
Why?
| | Sarcoidosis | 1 | 2023 | 162 | 0.170 |
Why?
| | Inflammation Mediators | 1 | 2023 | 510 | 0.160 |
Why?
| | Endovascular Procedures | 1 | 2025 | 372 | 0.160 |
Why?
| | Biomarkers | 9 | 2026 | 4207 | 0.160 |
Why?
| | Publishing | 1 | 2021 | 109 | 0.160 |
Why?
| | Interferon-gamma | 1 | 2023 | 790 | 0.160 |
Why?
| | Catecholamines | 2 | 2017 | 89 | 0.160 |
Why?
| | Neutrophil Infiltration | 1 | 2020 | 105 | 0.150 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2023 | 288 | 0.150 |
Why?
| | Multiple Trauma | 1 | 2020 | 115 | 0.150 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2022 | 484 | 0.140 |
Why?
| | Mitochondria | 1 | 2025 | 973 | 0.140 |
Why?
| | Mice | 4 | 2026 | 18172 | 0.140 |
Why?
| | Peripheral Arterial Disease | 1 | 2025 | 498 | 0.140 |
Why?
| | Serum Albumin | 1 | 2018 | 148 | 0.130 |
Why?
| | Extracellular Vesicles | 1 | 2019 | 160 | 0.130 |
Why?
| | Incidence | 1 | 2024 | 2826 | 0.130 |
Why?
| | E-Selectin | 1 | 2017 | 58 | 0.130 |
Why?
| | Time Factors | 4 | 2025 | 7006 | 0.130 |
Why?
| | Intracranial Hemorrhages | 1 | 2017 | 99 | 0.130 |
Why?
| | Electric Injuries | 1 | 2016 | 2 | 0.130 |
Why?
| | Adrenal Glands | 1 | 2017 | 79 | 0.130 |
Why?
| | Disease-Free Survival | 1 | 2018 | 716 | 0.120 |
Why?
| | Burns, Electric | 1 | 2016 | 26 | 0.120 |
Why?
| | Transcriptome | 1 | 2023 | 1015 | 0.120 |
Why?
| | RNA | 1 | 2023 | 929 | 0.120 |
Why?
| | Cells, Cultured | 1 | 2023 | 4167 | 0.120 |
Why?
| | Sympathetic Nervous System | 1 | 2017 | 175 | 0.120 |
Why?
| | Energy Drinks | 1 | 2015 | 3 | 0.120 |
Why?
| | Platelet Count | 3 | 2021 | 91 | 0.120 |
Why?
| | Dietary Supplements | 1 | 2020 | 582 | 0.120 |
Why?
| | Aged | 7 | 2025 | 25117 | 0.110 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2020 | 1225 | 0.110 |
Why?
| | Fluid Therapy | 1 | 2016 | 143 | 0.110 |
Why?
| | Cysteine-Rich Protein 61 | 1 | 2014 | 7 | 0.110 |
Why?
| | Pancreatic Neoplasms | 1 | 2023 | 895 | 0.110 |
Why?
| | Vascular Diseases | 1 | 2017 | 246 | 0.110 |
Why?
| | Blood Specimen Collection | 1 | 2014 | 37 | 0.110 |
Why?
| | Protein C | 1 | 2014 | 54 | 0.110 |
Why?
| | Cell Line | 1 | 2020 | 2878 | 0.110 |
Why?
| | Emergency Medical Services | 1 | 2021 | 682 | 0.100 |
Why?
| | Survival Rate | 1 | 2018 | 1995 | 0.100 |
Why?
| | Wounds, Nonpenetrating | 1 | 2017 | 311 | 0.100 |
Why?
| | Hemostatic Techniques | 1 | 2014 | 52 | 0.100 |
Why?
| | Texas | 1 | 2014 | 269 | 0.100 |
Why?
| | Case-Control Studies | 3 | 2016 | 3604 | 0.100 |
Why?
| | Disease Models, Animal | 3 | 2025 | 4483 | 0.100 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2014 | 316 | 0.090 |
Why?
| | Homeostasis | 1 | 2016 | 637 | 0.090 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2018 | 853 | 0.080 |
Why?
| | Oxidation-Reduction | 1 | 2014 | 1084 | 0.080 |
Why?
| | Apoptosis | 1 | 2019 | 2500 | 0.080 |
Why?
| | Predictive Value of Tests | 3 | 2025 | 2081 | 0.080 |
Why?
| | Severity of Illness Index | 2 | 2015 | 2927 | 0.080 |
Why?
| | Blood Coagulation Factors | 2 | 2022 | 54 | 0.070 |
Why?
| | Prognosis | 4 | 2019 | 4112 | 0.070 |
Why?
| | Young Adult | 7 | 2019 | 13878 | 0.070 |
Why?
| | Trauma Severity Indices | 2 | 2018 | 111 | 0.060 |
Why?
| | Cell Proliferation | 1 | 2014 | 2514 | 0.060 |
Why?
| | Trauma Centers | 2 | 2017 | 462 | 0.050 |
Why?
| | Longitudinal Studies | 2 | 2026 | 2980 | 0.050 |
Why?
| | Heparin, Low-Molecular-Weight | 1 | 2023 | 38 | 0.050 |
Why?
| | Aged, 80 and over | 3 | 2025 | 8020 | 0.050 |
Why?
| | Pilot Projects | 2 | 2022 | 1829 | 0.050 |
Why?
| | Multivariate Analysis | 2 | 2017 | 1508 | 0.050 |
Why?
| | Medical Futility | 1 | 2023 | 31 | 0.050 |
Why?
| | Biology | 1 | 2023 | 92 | 0.050 |
Why?
| | Reference Standards | 1 | 2023 | 181 | 0.050 |
Why?
| | Heparin | 1 | 2023 | 254 | 0.050 |
Why?
| | Reactive Oxygen Species | 1 | 2025 | 634 | 0.050 |
Why?
| | Vital Capacity | 1 | 2023 | 308 | 0.050 |
Why?
| | Immunomodulation | 1 | 2023 | 101 | 0.050 |
Why?
| | Cell Separation | 1 | 2023 | 310 | 0.050 |
Why?
| | Breast Neoplasms | 1 | 2014 | 2272 | 0.040 |
Why?
| | Immunization, Passive | 1 | 2021 | 88 | 0.040 |
Why?
| | Logistic Models | 2 | 2017 | 2102 | 0.040 |
Why?
| | B7-H1 Antigen | 1 | 2023 | 227 | 0.040 |
Why?
| | Leukocyte Reduction Procedures | 1 | 2020 | 27 | 0.040 |
Why?
| | Metabolomics | 1 | 2026 | 712 | 0.040 |
Why?
| | Intensive Care Units | 1 | 2026 | 874 | 0.040 |
Why?
| | Chemokine CCL2 | 1 | 2020 | 115 | 0.040 |
Why?
| | Proteomics | 1 | 2026 | 1152 | 0.040 |
Why?
| | Cold Temperature | 1 | 2020 | 199 | 0.040 |
Why?
| | Flow Cytometry | 1 | 2023 | 1185 | 0.040 |
Why?
| | In Vitro Techniques | 1 | 2020 | 1062 | 0.040 |
Why?
| | Tumor Microenvironment | 1 | 2023 | 717 | 0.040 |
Why?
| | Urokinase-Type Plasminogen Activator | 1 | 2017 | 30 | 0.030 |
Why?
| | Multicenter Studies as Topic | 1 | 2019 | 374 | 0.030 |
Why?
| | Edema | 1 | 2018 | 127 | 0.030 |
Why?
| | Treatment Outcome | 2 | 2025 | 11298 | 0.030 |
Why?
| | Antifibrinolytic Agents | 1 | 2017 | 59 | 0.030 |
Why?
| | Neutrophils | 1 | 2023 | 1124 | 0.030 |
Why?
| | Platelet Adhesiveness | 1 | 2016 | 14 | 0.030 |
Why?
| | Norepinephrine | 1 | 2017 | 191 | 0.030 |
Why?
| | Epinephrine | 1 | 2017 | 148 | 0.030 |
Why?
| | Models, Theoretical | 1 | 2020 | 585 | 0.030 |
Why?
| | Kaolin | 1 | 2015 | 5 | 0.030 |
Why?
| | Risk Assessment | 1 | 2025 | 3562 | 0.030 |
Why?
| | Methionine | 1 | 2016 | 158 | 0.030 |
Why?
| | ROC Curve | 1 | 2017 | 600 | 0.030 |
Why?
| | Arachidonic Acid | 1 | 2015 | 107 | 0.030 |
Why?
| | Fibrin Clot Lysis Time | 1 | 2014 | 10 | 0.030 |
Why?
| | Healthy Volunteers | 1 | 2015 | 213 | 0.030 |
Why?
| | Linear Models | 1 | 2017 | 857 | 0.030 |
Why?
| | Punctures | 1 | 2014 | 40 | 0.030 |
Why?
| | Partial Thromboplastin Time | 1 | 2014 | 52 | 0.030 |
Why?
| | Random Allocation | 1 | 2015 | 370 | 0.030 |
Why?
| | 3T3 Cells | 1 | 2014 | 152 | 0.030 |
Why?
| | Thromboplastin | 1 | 2014 | 72 | 0.030 |
Why?
| | Forkhead Box Protein O1 | 1 | 2014 | 35 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2019 | 1037 | 0.030 |
Why?
| | MCF-7 Cells | 1 | 2014 | 127 | 0.030 |
Why?
| | Survival Analysis | 1 | 2017 | 1328 | 0.030 |
Why?
| | Solubility | 1 | 2014 | 239 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2017 | 1284 | 0.030 |
Why?
| | Early Diagnosis | 1 | 2014 | 245 | 0.030 |
Why?
| | Forkhead Transcription Factors | 1 | 2014 | 201 | 0.030 |
Why?
| | Factor VIII | 1 | 2014 | 100 | 0.030 |
Why?
| | Femoral Artery | 1 | 2014 | 188 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2019 | 1642 | 0.020 |
Why?
| | Forecasting | 1 | 2014 | 384 | 0.020 |
Why?
| | Adolescent | 3 | 2017 | 22326 | 0.020 |
Why?
| | Reference Values | 1 | 2014 | 807 | 0.020 |
Why?
| | Hospitalization | 1 | 2023 | 2293 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2017 | 1977 | 0.020 |
Why?
| | MAP Kinase Signaling System | 1 | 2014 | 322 | 0.020 |
Why?
| | Hospital Mortality | 1 | 2017 | 952 | 0.020 |
Why?
| | Burns | 1 | 2016 | 357 | 0.020 |
Why?
| | Liver | 1 | 2019 | 1848 | 0.020 |
Why?
| | Cardiac Catheterization | 1 | 2014 | 547 | 0.020 |
Why?
| | Lung | 1 | 2023 | 4078 | 0.020 |
Why?
| | Cell Movement | 1 | 2014 | 969 | 0.020 |
Why?
| | Pregnancy | 1 | 2022 | 7113 | 0.020 |
Why?
| | Models, Biological | 1 | 2016 | 1821 | 0.020 |
Why?
| | Prevalence | 1 | 2015 | 2817 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2014 | 3362 | 0.020 |
Why?
| | Phenotype | 1 | 2014 | 3184 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2015 | 6324 | 0.010 |
Why?
| | Infant | 1 | 2015 | 9908 | 0.010 |
Why?
| | Child, Preschool | 1 | 2015 | 11634 | 0.010 |
Why?
| | United States | 1 | 2014 | 15447 | 0.010 |
Why?
| | Child | 1 | 2015 | 22562 | 0.010 |
Why?
|
|
Cardenas's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|